GlassScriptPhysician profile
Nicole Potucek Strand
NPI 1407367212
$18,002.83
in general payments reported to CMS, 2019-2025
31 companies · $4,757 in 2025
The $4,757 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,710 · 2022: $2,968 · 2023: $3,271 · 2024: $5,298 · 2025: $4,757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,671.70 |
| Education | $653.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,125.70 | 2021-2025 | |
| Janssen Biotech, INC. | $2,051.15 | 2021-2025 | Tremfya, Remicade, Simponi |
| Regeneron Healthcare Solutions, INC. | $1,637.00 | 2021-2025 | Dupixent |
| Leo Pharma INC. | $1,618.28 | 2021-2025 | Adbry, Anzupgo |
| Pfizer INC. | $1,451.67 | 2021-2025 | |
| Incyte Corporation | $1,063.03 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $1,053.77 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $997.73 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Amgen INC. | $816.00 | 2021-2025 | Otezla, Otezla, Enbrel |
| Genzyme Corporation | $623.21 | 2021-2025 | |
| Galderma Laboratories, L.P. | $548.49 | 2021-2025 | Nemluvio, Aklief |
| Ucb, INC. | $487.76 | 2021-2025 | Bimzelx |
| Dermavant Sciences, INC. | $455.30 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $403.29 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $378.38 | 2022-2024 | Sotyktu |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $261.57 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $227.23 | 2022-2025 | Cabtreo, Jublia |
| Almirall LLC | $155.05 | 2021-2025 | Klisyri, Seysara |
| Mayne Pharma Commercial LLC | $154.70 | 2021-2025 | |
| Organon LLC | $111.18 | 2025 | Vtama |
| Biofrontera INC. | $76.76 | 2021-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Journey Medical Corporation | $67.04 | 2022 | |
| Botanix Sb INC | $52.56 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $40.64 | 2024-2025 | Ycanth |
| Fresenius Kabi USA, LLC | $30.30 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.37 | 2024 | Cyltezo |
| Vyne Pharmaceuticals INC. | $23.51 | 2021 | |
| Array Biopharma INC | $20.73 | 2021-2022 | |
| Helsinn Therapeutics (U.S.), INC. | $16.86 | 2022 | |
| Epi Health, LLC | $14.46 | 2021 | |
| Lnhc, INC | $14.11 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Strand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.